Xuefeng Lin, Department of Cardiovascular Medicine, First Affiliated Hospital of Medical College of Xi'an Jiaotong University; Institute of Cardiovascular Channelopathy, Key Laboratory of Environment & Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education; Key Laboratory of Molecular Cardiology, Shannxi Province; No.277 Yanta West Road, Xi'an, 710061, P. R. China.
Aiqun Ma, Department of Cardiovascular Medicine, First Affiliated Hospital of Medical College of Xi'an Jiaotong University; Institute of Cardiovascular Channelopathy, Key Laboratory of Environment & Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education; Key Laboratory of Molecular Cardiology, Shannxi Province; No.277 Yanta West Road, Xi'an, 710061, P. R. China.
Pak J Med Sci. 2013 Apr;29(2):545-8. doi: 10.12669/pjms.292.2937.
To explore the effects of preoperative administration of conventional doses of atorvastatin plus trimetazidine on the myocardial injury of patients during the perioperative period of percutaneous coronary intervention (PCI).
475 cases of acute coronary syndrome patients before PCI were randomly divided into the control group (238 cases) and experimental group (237 cases).The control group was treated with conventional doses of atorvastatin calcium (20 mg each time, once a night), and the experimental group was treated with conventional doses of atorvastatin calcium plus trimetazidine hydrochloride (20 mg each time, tid) for 3 d. After PCI, preoperative and postoperative 24 h concentrations of serum creatine kinase MB isoenzyme (CK-MB), cardiac troponin I (cTnI) and high sensitivity C-reactive protein (hs-CRP) as well as activity of myeloperoxidase (MPO) were investigated. Left ventricular ejection fractions of the patients were then examined 4 weeks later.
Postoperative 24 h cTnI concentration and elevated MPO activity of the experimental group were significantly lower than those of the control group (P <0 05). CK-MB activities and hs-CRP concentrations of the two groups did not differ significantly (P> 0 05).
The administration of conventional doses of atorvastatin plus trimetazidine three days before PCI is able to protect the perioperative patients from myocardial injury.
探讨常规剂量阿托伐他汀联合曲美他嗪术前给药对经皮冠状动脉介入治疗（PCI）围术期患者心肌损伤的影响。
将 475 例急性冠脉综合征患者随机分为对照组（238 例）和实验组（237 例）。对照组给予常规剂量阿托伐他汀钙（每次 20mg，每晚 1 次）治疗，实验组给予常规剂量阿托伐他汀钙联合盐酸曲美他嗪（每次 20mg，tid）治疗 3d。PCI 后检测血清肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白 I（cTnI）和高敏 C 反应蛋白（hs-CRP）浓度及髓过氧化物酶（MPO）活性。4 周后检查患者左心室射血分数。
实验组术后 24h cTnI 浓度和升高的 MPO 活性明显低于对照组（P<0.05）。两组 CK-MB 活性和 hs-CRP 浓度差异无统计学意义（P>0.05）。
PCI 前 3 天给予常规剂量阿托伐他汀联合曲美他嗪可保护围术期患者免受心肌损伤。
